Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scheid

Showing results (1211-1220 of 1,291) with videos related to

Pageof 130
Sort By:
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Journal of the American Chemical Society|January 5, 2023
The Myxobacterial Antibiotic Myxovalargin: Biosynthesis, Structural Revision, Total Synthesis, and Molecular Characterization of Ribosomal InhibitionTimm O Koller, Ullrich Scheid, Teresa Kösel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
The Lancet. Haematology|November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialHartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Science Translational Medicine|March 1, 2019
Patients with autism spectrum disorders display reproducible functional connectivity alterationsŠtefan Holiga, Joerg F Hipp, Christopher H Chatham, et al.
Cancer Research|October 3, 2025
FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid LeukemiaMelissa Zwick, Bastian Zinkel, Corinna Spohr, et al.
Advances in Therapy|November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMentHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Leukemia|August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trialH Goldschmidt, H M Lokhorst, E K Mai, et al.
Scientific Reports|May 7, 2021
Association between ACE2 and TMPRSS2 nasopharyngeal expression and COVID-19 respiratory distressÁtila Duque Rossi, João Locke Ferreira de Araújo, Tailah Bernardo de Almeida, et al.
Pageof 130

Showing results (1211-1220 of 1,291) with videos related to

Sort By:
Pageof 130
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
Journal of the American Chemical Society|January 5, 2023
The Myxobacterial Antibiotic Myxovalargin: Biosynthesis, Structural Revision, Total Synthesis, and Molecular Characterization of Ribosomal InhibitionTimm O Koller, Ullrich Scheid, Teresa Kösel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
The Lancet. Haematology|November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialHartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Science Translational Medicine|March 1, 2019
Patients with autism spectrum disorders display reproducible functional connectivity alterationsŠtefan Holiga, Joerg F Hipp, Christopher H Chatham, et al.
Cancer Research|October 3, 2025
FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid LeukemiaMelissa Zwick, Bastian Zinkel, Corinna Spohr, et al.
Advances in Therapy|November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMentHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Leukemia|August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trialH Goldschmidt, H M Lokhorst, E K Mai, et al.
Scientific Reports|May 7, 2021
Association between ACE2 and TMPRSS2 nasopharyngeal expression and COVID-19 respiratory distressÁtila Duque Rossi, João Locke Ferreira de Araújo, Tailah Bernardo de Almeida, et al.
Pageof 130